Results 241 to 249 of about 1,093,896 (249)

Development of new pyrrolopyrimidine-based inhibitors of Janus kinase 3 (JAK3)

Bioorganic and Medicinal Chemistry Letters, 2007
Adam Golebiowski, John C Vanrens, Michael P Clark   +2 more
exaly  

Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib

Journal of the American Academy of Dermatology, 2017
Victor Huang, Deep Joshipura, Alice B Gottlieb   +2 more
exaly  

Janus kinase inhibitors in dermatology: A systematic review

Journal of the American Academy of Dermatology, 2017
Yuval Ramot, Abraham Zlotogorski
exaly  

Topical Janus kinase inhibitors: A review of applications in dermatology

Journal of the American Academy of Dermatology, 2018
Natasha Atanaskova Mesinkovska, Margit Lw Juhász, Anna-Marie Hosking   +2 more
exaly  

Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate

Journal of the American Academy of Dermatology, 2015
Brett King
exaly  

Ocular Immunology and Inflammation

Ocular Immunology and Inflammation, 2019
Arnd Heiligenhaus, Carsten Heinz
exaly  

Case report: Effectiveness of Janus kinase inhibitors in the management of isolated noninfectious uveitis: a case series

Frontiers in Pharmacology
Polona Jaki Mekjavic, Nataša Vidovič Valentinčič, Matija Tomsic   +2 more
exaly  

Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)

Journal of the American Academy of Dermatology
Colleen Hamilton, Natasha A Mesinkovska, Charles Lynde   +2 more
exaly  

Systemic Janus kinase inhibitor treatment for vitiligo: An evidence-based review

Journal of the American Academy of Dermatology
Jensen Yeung, Siddhartha Sood
exaly